医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
4期
96-97
,共2页
支气管扩张%大咯血%奥曲肽%垂体后叶素
支氣管擴張%大咯血%奧麯肽%垂體後葉素
지기관확장%대각혈%오곡태%수체후협소
Bronchiectasis%Big haemoptysis%Mr Qu peptide%Pituitrin
目的:观察奥曲肽在支气管扩张伴大咯血治疗中的疗效及不良反应。方法:在维持呼吸、循环稳定基础上,将患者随机分成对照组(垂体后叶素组)、实验组(奥曲肽组),观察两组疗效及不良反应。计数资料用卡方检验进行统计分析。结果:患者共60例,男34例,女26例;年龄42~81岁,平均年龄51岁;在性别、年龄,咯血量等方面,差异无统计学意义(P>0.05)。实验组总有效率90.6%,对照组79.1%,x2=6.122,P<0.05,有统计学差异。结论:在支气管扩张大咯血治疗中奥曲肽疗效可靠,副作用少。
目的:觀察奧麯肽在支氣管擴張伴大咯血治療中的療效及不良反應。方法:在維持呼吸、循環穩定基礎上,將患者隨機分成對照組(垂體後葉素組)、實驗組(奧麯肽組),觀察兩組療效及不良反應。計數資料用卡方檢驗進行統計分析。結果:患者共60例,男34例,女26例;年齡42~81歲,平均年齡51歲;在性彆、年齡,咯血量等方麵,差異無統計學意義(P>0.05)。實驗組總有效率90.6%,對照組79.1%,x2=6.122,P<0.05,有統計學差異。結論:在支氣管擴張大咯血治療中奧麯肽療效可靠,副作用少。
목적:관찰오곡태재지기관확장반대각혈치료중적료효급불량반응。방법:재유지호흡、순배은정기출상,장환자수궤분성대조조(수체후협소조)、실험조(오곡태조),관찰량조료효급불량반응。계수자료용잡방검험진행통계분석。결과:환자공60례,남34례,녀26례;년령42~81세,평균년령51세;재성별、년령,각혈량등방면,차이무통계학의의(P>0.05)。실험조총유효솔90.6%,대조조79.1%,x2=6.122,P<0.05,유통계학차이。결론:재지기관확장대각혈치료중오곡태료효가고,부작용소。
Objective Observe the octreotide in bronchiectasis with big hemoptysis treatment the curative effect and adverse reactions.Methods Patients were randomly divided into control group (pituitrin group), the experimental group (the peptide group), to observe the curative effect and adverse reaction in both groups.Results A total of 60 patients with, male 34 cases, female 26 cases; Aged 42-81, the average age of 51 years old; In gender, age, amount of haemoptysis, etc., there was no statistically significant difference (P > 0.05). Group total effectiveness 90.6%, control group 79.1%, x2 = 6.122,P < 0.05, statistically significant.Conclusions In the big hemoptysis treatment of bronchiectasis Mr Qu peptide reliable curative effect, less side effects.